<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431286</url>
  </required_header>
  <id_info>
    <org_study_id>NP297/12</org_study_id>
    <secondary_id>2012/11298-8</secondary_id>
    <nct_id>NCT02431286</nct_id>
  </id_info>
  <brief_title>Palonosetron Associated to Aprepitant in Prophylaxis of PONV</brief_title>
  <acronym>PONV</acronym>
  <official_title>Evaluation of Palonosetron and Palonosetron/Aprepitant in Post Operative Nausea and Vomiting Incidence in Oncological Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate if aprepitant in association with palonosetron
      and dexamethasone could reduce the incidence of PONV in high-risk patients for this symptom,
      undergoing cancer surgery mastectomies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative nausea and vomiting (PONV) is a common anesthetic complication that occurs in
      approximately 30% of the surgical population and can reach up to 70% in high risk patients
      for PONV. Advances have been made to prevent PONV, but the incidence is still high in certain
      groups of patients. In high risk patients, pharmacologic intervention should consist of
      multimodal therapy, targeting different mechanisms of action. The objective of this study is
      to investigate if aprepitant in association with palonosetron and dexamethasone could reduce
      the incidence of PONV in high-risk patients for this symptom, undergoing cancer surgery
      mastectomies. METHODS: this is a randomized and double blind clinical trial. Female high-risk
      patients for PONV(Apfel score 3 or 4) scheduled for mastectomy that agree with the study and
      signed the informed consent, are randomly distributed into one of two groups: Group A,
      aprepitant 80 mg per os one hour before the surgery and Group B will receive placebo by the
      same route one hour before surgery, in a blinded way. After induction of anesthesia,
      dexamethasone 4 mg and palonosetron 0,075mg are intravenously administered to all patients.
      After the end of the surgery, a patient-controlled analgesia (PCA) device will be
      intravenously inserted in all patients. In the postoperative period, patients will be
      evaluated for nausea, vomiting and pain intensity in the recovery room and after 24 hours
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of postoperative nausea and vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>intensity of nausea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative pain measured by Verbal and descriptive scale</measure>
    <time_frame>24 hours</time_frame>
    <description>pain intensity in the first 24 hours after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Aprepitant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient will receive aprepitant 80 mg per os one hour before surgery; palonosetron and dexamethasone will be intravenously administered during surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient will receive placebo per os one hour before surgery; palonosetron and dexamethasone will be intravenously administered during surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>aprepitant will be administered in preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively</description>
    <arm_group_label>Aprepitant</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered in the preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone and plonosetron will be administered intraoperatively in both groups, durong surgery</description>
    <arm_group_label>Aprepitant</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients submitted to breast cancer surgery

          -  non smokers

        Exclusion Criteria:

          -  any contraindication to one of the drugs

          -  mental disease

          -  inability to understand the method or refusal to participate in the research
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hazem a Ashmawi, phD</last_name>
    <role>Study Director</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Sousa, phD</last_name>
    <phone>551126616680</phone>
    <email>angela.sousa@icesp.org.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Angela Maria Sousa</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>01403010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>angela sousa, phD</last_name>
      <phone>3893-2000</phone>
      <phone_ext>6680</phone_ext>
      <email>angela.sousa@icesp.org.br</email>
    </contact>
    <investigator>
      <last_name>Thiago Grigio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>angela sousa, phD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>hazem ashmawi, phD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Moon HY, Baek CW, Choi GJ, Shin HY, Kang H, Jung YH, Woo YC, Kim JY, Park SG. Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial. BMC Anesthesiol. 2014 Aug 10;14:68. doi: 10.1186/1471-2253-14-68. eCollection 2014.</citation>
    <PMID>25165427</PMID>
  </results_reference>
  <results_reference>
    <citation>George E, Hornuss C, Apfel CC. Neurokinin-1 and novel serotonin antagonists for postoperative and postdischarge nausea and vomiting. Curr Opin Anaesthesiol. 2010 Dec;23(6):714-21. doi: 10.1097/ACO.0b013e32833f9f7b. Review.</citation>
    <PMID>20871394</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2015</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2015</study_first_posted>
  <last_update_submitted>April 30, 2015</last_update_submitted>
  <last_update_submitted_qc>April 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nausea and vomiting, postoperative</keyword>
  <keyword>emesis, postoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 16, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

